8RP logo

Celon Pharma DB:8RP Stock Report

Last Price

€5.94

Market Cap

€335.4m

7D

1.2%

1Y

66.2%

Updated

07 Jan, 2025

Data

Company Financials +

My Notes

Capture your thoughts, links and company narrative

Celon Pharma S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Celon Pharma
Historical stock prices
Current Share Pricezł5.94
52 Week Highzł7.14
52 Week Lowzł3.23
Beta0.78
1 Month Change1.02%
3 Month Change-7.62%
1 Year Change66.15%
3 Year Change-14.53%
5 Year Changen/a
Change since IPO-39.63%

Recent News & Updates

Recent updates

Shareholder Returns

8RPDE PharmaceuticalsDE Market
7D1.2%3.4%2.0%
1Y66.2%-14.7%9.6%

Return vs Industry: 8RP exceeded the German Pharmaceuticals industry which returned -14.5% over the past year.

Return vs Market: 8RP exceeded the German Market which returned 9.1% over the past year.

Price Volatility

Is 8RP's price volatile compared to industry and market?
8RP volatility
8RP Average Weekly Movement7.0%
Pharmaceuticals Industry Average Movement5.6%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.7%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 8RP's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 8RP's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2002562Maciej Wieczorekwww.celonpharma.com

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland.

Celon Pharma S.A. Fundamentals Summary

How do Celon Pharma's earnings and revenue compare to its market cap?
8RP fundamental statistics
Market cap€335.35m
Earnings (TTM)€4.34m
Revenue (TTM)€49.14m

77.2x

P/E Ratio

6.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8RP income statement (TTM)
Revenuezł209.54m
Cost of Revenuezł64.10m
Gross Profitzł145.43m
Other Expenseszł126.92m
Earningszł18.51m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.34
Gross Margin69.41%
Net Profit Margin8.83%
Debt/Equity Ratio0%

How did 8RP perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

23%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 09:05
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Celon Pharma S.A. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamil KliszczBiuro maklerskie mBanku
Beata Szparaga-WasniewskaBiuro maklerskie mBanku
Vladimira UrbankovaErste Group Bank AG